Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

Trial Profile

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Nirogacestat (Primary)
  • Indications Fibroma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2017 Planned End Date changed from 30 Dec 2018 to 12 Oct 2019.
    • 28 Mar 2017 Results published in the Journal of Clinical Oncology
    • 18 Jan 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top